Physician profile

Micah B Shook

Internal Medicine · Hendersonville, NC

NPI 1497320956

$214.54

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$105.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $42.65 2022-2023
Abbvie INC. $41.87 2021
Amgen INC. $32.18 2023 Avsola, Amjevita
Lundbeck LLC $22.77 2023 Vyepti
Eisai INC. $16.15 2023
Novartis Pharmaceuticals Corporation $15.31 2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $15.21 2021
Pfizer INC. $14.27 2021
Exact Sciences Corporation $14.13 2023 Cologuard Collection Kit

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Micah B Shook

$214.54

in general payments reported 2019-2025

Years
2021-2023
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/10249801/micah-b-shook

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.